Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2014

View Archived Issues

Eisai presents highlights of third quarter of fiscal 2013

Astellas reflects on accomplishments of third quarter of fiscal 2013

Researchers report data from phase I/II study of retinal gene therapy in patients with choroideremia

Ono Pharmaceutical updates milestones of third quarter of fiscal 2013

Phase II results show prolonged immune responses with DN24-02 in patients with urothelial cancer

Mutant recombinant protective antigen vaccine protects animals from anthrax

Hisamitsu Pharmaceutical reports data from phase II study of HP-3000

AnGes prepares global phase III study of Collategene

Takeda reports development of 5-HT3 receptor antagonists

Dainippon Sumitomo Pharma patent describes coagulation factor XIa inhibitor

e-Therapeutics begins dosing in phase I study of oral ETS-2101

Chinese researchers patent novel CETP inhibitors

Kyowa Hakko Kirin alters supplemental application for Poteligio in Japan

Metabrain Research divulges compounds with potential for treatment of type 2 diabetes

Alcobra files IND to conduct phase III trial of MG-01CI in adults with ADHD

Ares Trading patent reports novel gamma-secretase modulators

Soluble guanylate cyclase activators reported in Bayer patent

Pfizer to perform phase Ib trial of PF-06342674 in MS

Novartis researchers reveal histamine H3 receptor antagonists

Hutchison MediPharma discloses novel PI3Kdelta inhibitors

Asthma treatment flutiform launched in France

MLN-7243 to be evaluated in phase I cancer trial

FDA grants orphan drug designation to NeuroVax for pediatric MS

Eravacycline demonstrates efficacy in animal models of Francisella tularensis infection

Phase II study data do not support development of ADX-71149 for anxious depression

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026